Who are we?
Bactera is a Germany-based biomedical company focused on high-resolution microbiome profiling and the development of regulated microbiome therapeutics, in particular fecal microbiota transplantation (FMT). The company was founded by certified experts from microbiology, human medicine, bioinformatics, and computer science with many years of experience in clinical research, sequencing technologies, and translational science. Our team has contributed to multiple projects investigating how the human gut microbiome influences metabolic, immune, and neurological processes, and how this knowledge can be translated into structured medical applications. Our work combines the newest modern sequencing technologies, computational analysis, and clinical collaboration to better understand microbial ecosystems and their role in human health. By integrating expertise from microbiology, medicine, and data science, Bactera aims to build a scientific and technological foundation for microbiome-based medicine.
What we do today.
Through our Microbiome 360° platform, we perform shotgun metagenomic sequencing of stool samples to characterize the complete microbial ecosystem of the human gut. Unlike simplified microbiome tests that analyze only selected bacterial markers, our approach evaluates the entire microbial DNA present in a sample, allowing detailed identification of bacteria, viruses, fungi, and parasites.
The resulting reports provide structured insights into your microbiome diversity. These analyses are designed to support scientific understanding of the gut microbiome and provide individuals and professionals with a deeper view of the microbial communities that inhabit the human intestine.
What we are building.
Beyond sequencing, Bactera is developing a capsule-based fecal microbiota transplantation (FMT) platform designed to restore disrupted microbial ecosystems.
FMT involves the transfer of a complete microbial community from a screened healthy donor to a recipient. Unlike probiotic approaches that introduce only a limited number of strains, FMT replaces the entire microbial ecosystem and has demonstrated significant therapeutic potential in clinical research.
Our focus areas.
Microbiome 360°.
FMT Capsules.
Our research.
Collaborate with us.
Timeline.
2025
Launch of Bactera.
Bactera, a Germany-based biomedical pioneer, officially launches to advance the field of regulated microbiome therapeutics. Founded by a multidisciplinary team of experts across microbiology, human medicine, bioinformatics, and computer science, the company bridges the gap between clinical research and translational science.
2026
Microbiome 360°
Bactera is a biomedical startup redefining gut health through advanced microbiome analysis. We are proud to launch the Microbiome 360°, bringing health insights to patients, clinicians, and researchers alike. Using high-resolution shotgun sequencing, our technology provides a precise, comprehensive map of the gut’s microbial landscape to better understand its impact on your health.
2027
Capsule-based FMT.
Looking ahead to early 2027, Bactera is preparing to expand the frontiers of gut health with our upcoming capsule-based FMT treatment. Fecal microbiota transplantation (FMT) restores gut health by transferring a screened microbiome from a healthy donor. We are transforming this complex clinical procedure into a safe, non-invasive capsule-based system, making advanced microbiome restoration accessible through simple oral delivery.
Get in touch with us
Have a question or want to learn more? We'd love to hear from you. Our team is here to help.
✔️ We answer all your questions.
✔️ We advise individually.
✔️ We respond to all inquiries.